The Government says commercial clinical trials in the UK are now being set up in an average of 122 days, down from 169 days in the equivalent six month period a year earlier. This is excellent news for research, patients and anyone who has watched a form mature into a historical document. The 150 day target has been met with such enthusiasm that the calendar is now preparing a keynote speech about innovation.
The figures, published on 15 April and covering data up to March 2026, concern commercial interventional trials. The Government attributes the reduction to standardised processes, less unnecessary paperwork and investment in research infrastructure. Several large institutions have apparently discovered that a system moves faster when it is not required to carry its own filing cabinet from room to room.
The 150 day target was intended to get trials running within that period. The latest average is below it, so the stopwatch has recorded a pleasing result and will now be invited to every meeting. Somewhere, a spreadsheet is being considered for a senior leadership role because it once understood a deadline.
This is not a minor administrative victory wearing a laboratory coat. Faster setup can help researchers begin work sooner and may give patients earlier access to trials. The Government highlighted a chronic obstructive pulmonary disease study that took its first patients in 81 days and a bowel cancer treatment trial that began in 70 days. Those figures involve real people, which makes the achievement worth more than a ceremonial handshake between two filing systems.
There is, however, a familiar institutional temptation to treat one successful target as proof that the entire system has been cured. The announcement calls the milestone a step forward rather than a finish line. This is wise. Britain has repeatedly shown that a successful reform can be converted into a permanent committee before the biscuits arrive.
The next challenge is maintaining the improvement, increasing participation and ensuring that speed does not replace proper safeguards. A clinical trial is not a parcel being chased by a delivery driver. It requires care, scrutiny and people willing to ask awkward questions before anyone swallows anything. The stopwatch can celebrate without being allowed to approve the medicine.
The calendar has accepted the result. It has retired its objection form, awarded itself a medal and submitted an expenses claim for the ceremony. The claim was returned because it had been filed under future achievements.
Source: GOV.UK.
